Dr. Maka Siamashvili, MD
Claim this profileUniversity of Maryland
Studies Diabetes
Studies Type 1 Diabetes
5 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Maka Siamashvili, MD is currently running
Fluoxetine + DHEA
for Type 1 Diabetes
(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.
Recruiting0 awards Phase < 14 criteria
Glucose Clamp Study
for Low Blood Sugar
Hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. To date no studies appear to have investigated the effects of differing levels of hypoglycemia on the vasculature and pro-atherothrombotic balance during hypoglycemia in healthy man. The specific aim of our study will be to determine the effects of differing levels of hypoglycemia on in-vivo vascular biologic mechanisms in a healthy population.
Recruiting1 award Phase < 11 criteria
More about Maka Siamashvili, MD
Clinical Trial Related8 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Maka Siamashvili, MD has experience with
- DHEA
- Fluoxetine
- Fluoxetine And DHEA
- Placebo Oral Tablet
- SmartAlbu
- Glucose Clamp
Breakdown of trials Maka Siamashvili, MD has run
Diabetes
Diabetes Mellitus
Hypoglycemia
Low Blood Sugar
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Maka Siamashvili, MD specialize in?
Maka Siamashvili, MD focuses on Diabetes and Type 1 Diabetes. In particular, much of their work with Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Maka Siamashvili, MD currently recruiting for clinical trials?
Yes, Maka Siamashvili, MD is currently recruiting for 2 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Maka Siamashvili, MD has studied deeply?
Yes, Maka Siamashvili, MD has studied treatments such as DHEA, Fluoxetine, Fluoxetine and DHEA.
What is the best way to schedule an appointment with Maka Siamashvili, MD?
Apply for one of the trials that Maka Siamashvili, MD is conducting.
What is the office address of Maka Siamashvili, MD?
The office of Maka Siamashvili, MD is located at: University of Maryland, Baltimore, Maryland 21201 United States. This is the address for their practice at the University of Maryland.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.